Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess rate of disease relapse and hazard rate of disease
relapse after neoadjuvant therapy based on the statuses of pathologic complete response or
non-pathologic complete response, and postoperative adjuvant therapy.
Phase:
Early Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute